VX-765: Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a pro-drug that selectively inhibits caspase-1, enabling targeted study of inflammasome-driven inflammation and pyroptosis in vitro and in vivo (Israelov et al., 2020). The compound is metabolized to VRT-043198, which blocks IL-1β and IL-18 release without impacting IL-6, IL-8, or TNFα (APExBIO product page). VX-765 restores blood-brain barrier integrity after inflammatory insult by reducing PBMC adhesion and transmigration (Israelov et al., 2020). The agent is orally absorbed, insoluble in water, but highly soluble in DMSO and ethanol, making it suitable for diverse research workflows (product specification). VX-765 is under investigation for therapeutic indications in CNS and systemic inflammatory diseases (Israelov et al., 2020).

Biological Rationale

Caspase-1 (interleukin-1 converting enzyme, ICE) is a cysteine protease central to the maturation of pro-inflammatory cytokines IL-1β and IL-18. Upon activation by inflammasomes—multiprotein complexes responding to microbial or danger signals—caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active, secreted forms (Israelov et al., 2020). These cytokines drive fever, leukocyte recruitment, and barrier dysfunction in acute and chronic inflammation. Caspase-1 also mediates pyroptosis, a lytic form of programmed cell death in macrophages and other myeloid cells, which is triggered by intracellular pathogens or cytosolic danger signals. Excessive caspase-1 activation is implicated in rheumatoid arthritis, neuroinflammation, and HIV-associated CD4 T-cell loss (APExBIO; related review). Targeting caspase-1 enables precise dissection of these inflammatory pathways and offers a therapeutic hypothesis for disease modulation.

Mechanism of Action of VX-765

VX-765 is an orally bioavailable pro-drug that is rapidly converted in vivo to VRT-043198, the active moiety. VRT-043198 binds selectively to the active site of caspase-1, inhibiting its protease activity. This inhibition blocks the cleavage and secretion of IL-1β and IL-18, while sparing the processing or release of unrelated cytokines such as IL-6, IL-8, TNFα, and IL-α (APExBIO). VX-765 does not significantly inhibit other caspases (e.g., caspase-3, -8, -9) at pharmacologically relevant concentrations, minimizing off-target effects (mechanistic detail). This selectivity enables researchers to specifically interrogate ICE-like protease activity in diverse cellular and animal models. In cell-based assays, VX-765 reduces inflammasome-driven cytokine secretion and prevents pyroptotic cell death in macrophages, monocytes, and lymphoid tissues. The compound's oral bioavailability and metabolic stability have supported its progression into clinical studies for epilepsy and inflammatory disorders (Israelov et al., 2020).

Evidence & Benchmarks

• VX-765 restores blood-brain barrier (BBB) integrity in vitro after paraoxon-induced injury, reducing PBMC adhesion, transmigration, and increasing VE-cadherin protein levels (Israelov et al., 2020).
• In animal models, oral VX-765 administration significantly decreases inflammation and IL-1β/IL-18 secretion in collagen-induced arthritis and skin inflammation (preclinical data, APExBIO).
• VX-765 prevents CD4 T-cell pyroptosis in ex vivo HIV-infected lymphoid tissues in a dose-dependent manner (see related article).
• The compound shows high solubility in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonication) but is insoluble in water (APExBIO).
• Enzyme inhibition assays with VX-765 are optimally performed at pH 7.5 in buffered conditions to stabilize enzyme activity (see best practices).
• VX-765 selectively inhibits caspase-1, with negligible effect on caspase-8 or -9–mediated endothelial cell apoptosis (Israelov et al., 2020, see Results section).

This article extends previous discussions (see BBB-specific review) by integrating direct evidence from human and animal BBB models, emphasizing translational neuroinflammation outcomes.

Applications, Limits & Misconceptions

VX-765 is employed to dissect caspase-1-dependent pathways in basic and translational research, including:

• Interrogation of inflammasome signaling and pyroptosis in macrophages and monocytes.
• Modeling cytokine-driven neuroinflammation and BBB dysfunction.
• Assessing the role of IL-1β/IL-18 in arthritis, skin inflammation, and HIV pathology.
• Preclinical evaluation of anti-inflammatory and neuroprotective therapies.

For a broader mechanistic perspective—including RNA Pol II and cell death pathway interplay—see this in-depth analysis. Here, we focus on experimental specificity and translational benchmarks.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit all caspases; it is highly selective for caspase-1 and does not block caspase-8 or -9 at standard doses (Israelov et al., 2020).
• IL-6, IL-8, TNFα, and IL-α release are unaffected by VX-765, limiting its use to IL-1β/IL-18-driven pathways (APExBIO).
• VX-765 is insoluble in water and must be dissolved in DMSO or ethanol for experimental use (APExBIO).
• Long-term storage as a solution is not recommended due to hydrolytic instability; store desiccated at -20°C (APExBIO).
• Inhibition of caspase-1 does not address non-inflammasome-mediated cell death or pathology (see related discussion).

Workflow Integration & Parameters

To use VX-765 effectively in laboratory research:

• Dissolve VX-765 in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic aid); avoid water-based solvents (product specification).
• Store solid VX-765 desiccated at -20°C. Prepare solutions fresh or use within short-term experimental windows.
• In enzyme inhibition assays, use buffered conditions (pH 7.5) with stabilizers as recommended in the protocol (benchmarks).
• For in vivo studies, VX-765 can be administered orally; dosing should follow preclinical pharmacokinetic guidelines.
• Reference the APExBIO VX-765 (A8238) kit for full handling and safety information.

This article clarifies experimental boundaries and specificity, updating prior resources by integrating recent peer-reviewed BBB and neuroinflammation data.

Conclusion & Outlook

VX-765 is a benchmark tool for dissecting caspase-1-dependent inflammation and cell death, with demonstrated efficacy in blood-brain barrier, arthritis, and infectious disease models. Its selectivity and oral bioavailability have propelled it into translational research for CNS and systemic inflammatory disorders. Ongoing studies will further define its therapeutic index, application scope, and integration with next-generation anti-inflammatory strategies. For the most current protocols and safety data, consult the APExBIO VX-765 product page.